Imaging the effect of HSP90 inhibitor AUY922 on VEGF by means of 89Zr-bevacizumab PET. A side study to the phase I-II study with AUY922 in adult patients with advanced solid malignancies, or either HER2 or ER positive locally advanced or metastatic breast cancer: protocol CAUY922A2101.

Completed

• Conditions: breast cancer; mammary carcinoma; 10006291; 10006232

• Registration Number: NL-OMON33855
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 11

Inclusion Criteria

- patients with ER positive, hormone therapy refractory breast cancer
- participation in the phase I-II trial with HSP90 inhibitor AUY922 (in- and exclusion criteria for the study with AUY922 are described in protocol CAUY922A2101 -METc 2008.237-, section 5.1 and 5.2 (p 37-40).

Exclusion Criteria

- no participation in the phase I-II trial with HSP90 inhibitor AUY922

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Measurement of decreased VEGF-levels compared to baseline, as a reflection of<br /><br>response to HSP90 inhibitor AUY922. A decline is defined as at least a 30%<br /><br>decrease of the mean SUV in a maximum of three lesions. These lesions will have<br /><br>a size of at least 2 cm (on the baseline CT), and will show the highest uptake<br /><br>on baseline 89Zr-bevacizumab scan (on which they are predefined). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>